Regulus Therapeutics Inc.
RGLS
Classement en actions
#17340
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prix de l'action
$8.16
Dernière synchronisation: 2025-06-26
Capitalisation boursière
$234.57M
Changement (1 jour)
0.00%
Changement (1 an)
-88.86%
Pays
US
Échange Regulus Therapeutics Inc. (RGLS)
Catégorie
Healthcare
Historique du rendement du dividende pour Regulus Therapeutics Inc. (RGLS)
Le rendement du dividende (TTM) de Regulus Therapeutics Inc. (symbole boursier : RGLS) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Regulus Therapeutics Inc. (RGLS) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
| Année | Rendement du dividende | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
| Entreprise | Rendement du dividende | Pays |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
